ReviewPediatric research2026
Advances in treatment and prevention of pulmonary thromboembolism associated with Mycoplasma pneumoniae pneumonia in children.
Review in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, there has been a significant increase in reported cases of pulmonary thromboembolism associated with Mycoplasma pneumoniae pneumonia in pediatric patients, and its standardized treatment and effective prevention have increasingly attracted clinical attention. This article reviews the latest treatment approach for pulmonary thromboembolism complicated by Mycoplasma pneumoniae pneumonia in children, including anticoagulant therapy, systemic thrombolytic therapy, interventional therapy, and surgical therapy. Meanwhile, progress in research on the risk factors of this condition is also reviewed, aiming to provide new directions for future preventive studies. IMPACT: While several reviews have addressed the clinical characteristics of pulmonary thromboembolism (PTE) associated with Mycoplasma Pneumoniae pneumonia (MPP) in pediatric patients, there remains a lack of comprehensive syntheses focusing specifically on treatment and prevention. This review provides an integrated analysis of the latest evidence on treatment strategies over the past 5 years, facilitating informed clinical decision-making. Moreover, this review is the first to systematically map the studies on the risk factors of PTE induced by MPP, directly informing the directions of future preventive studies.
Identifiers
41588250What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.